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Objectives: to study the role of smoking, lipids, lipoprotein (a), and autoantibodies against oxidised low density lipoprotein
(Ab-oxLDL) in the expansion of small abdominal aortic aneurysms (AAA). To study the role of Ab-oxLDL and lp(a) in
the progression of lower limb atherosclerosis.
Methods and Materials: one hundred and thirty-eight male patients with AAA were interviewed, examined, and their
serum lipids and S-Ab-oxLDL determined. Of these, 117 were followed annually with ultrasound and underwent control
scans and blood pressure measurements for a mean of 2.5 (range 1–5) years.
Results: initial AAA size, smoking and level of triglycerides were positively correlated to increased aneurysmal expansion,
while beta-blocker medication was associated with decreased expansion. Besides initial AAA size, only smoking had
persisting significance after adjustment of the other significant variables. Initial ankle brachial pressure index (ABI) and
Lp(A) but not ab-oxLDL were significantly correlated to ABI change.
Conclusion: smoking cessation may inhibit aneurysmal expansion. Lipids seem to play a minor role in the progression
of AAA.
Key Words: Smoking; Lipids; Oxidized low density lipoprotein; Lipoprotein (a); Abdominal aortic aneurysm; Athero-
sclerosis; Progression.
Introduction Patient sera were analysed for IgG antibodies against
oxidised LDL by means of an enzyme-linked im-
Predicting the expansion of small abdominal aortic munosorbent assay (ELISA) using oxLDL-coated
aneurysms (AAA) is important for clinical man- microtitre plates, as previously described.7,8
agement. Lipoprotein (A) (LpA) levels are related to P-Lipoprotein a (Lp(a)) was quantified with earlier
atherosclerotic disease but the relationship between reported and validated immunoradiometric assay
LpA-levels and the progression of AAA has not been (IRMA) (Pharmacia Diagnostics, Sweden).9
analysed.1 S-total-cholesterol, S-high density lipoprotein
Oxidized LDL is implicated in the initial damage (HDL), and S-triglycerides were determined by com-
of the vascular endothelium.2–4 The concentration of mercial assays, while S-LDL was calculated as: S-
antibodies against oxidised LDL (Ab-oxLDL) is el- cholesterol – S-HDL+(0.45∗S-triglycerides).10
evated in patients with acute myocardial infarction One hundred and seventy men had an AAA diag-
(AMI)2 and carotid stenosis.2,3 The correlation was nosed at screening (4.0%).11,12 Complete data were
increased in cases with hypertriglyceridaemia.5 The available in 138 cases (82%). Twenty-one were above
role of oxidised LDL in the pathogenesis of AAA is 5 cm and referred for surgery, and the remaining 87%
unknown. were offered annual ultrasound scans. Of these, 124
The aim of the study was to relate AAA expansion have now been followed for 1–5 years (average 2.5
with lipids, Lp(A) and Ab-oxLDL levels. years). Blood samples were complete in 117 (94%) of
these patients. The mean expansion rate was mean 2.6Material and Methods
mm/year (SD:2.6). The ABI change was on average
−2.2%/year (SD:6.8). The interobserver variationsDetails of our AAA screening programme have been
(def.: 2SD) of aortic diameter and ABI-change werepublished previously.6
1.68 mm,13 0.16,14 respectively. The intra-assay co-
efficients of variation of Ab-oxLDL and Lp(a) were∗ Please address all correspondence to: J. S. Lindholt, Lærkevej 11,
8900 Randers, Denmark. 10% and 2.2%, respectively. The interassay coefficients
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of variation of Ab-oxLDL and Lp(a) were 25% and apparently has only been reported once29 to be cor-
related with expansion. This may be due to the as-3.1%, respectively.9 The same assays were used for all
the samples. sociation with the frequently coexisting atherosclerotic
diseases, or due to the use of unreliable data obtainedAlso, Wilcoxon’s rank sum test and Spearman’s
rank correlation analysis were used for the univariate by interviews. The latter bias could be omitted by
cotinine measurements.23,29 Our smoking data was ob-analyses, while multiple linear regression analyses
only were performed in significant univariate findings tained from a questionnaire that was completed at
home before the initial consultation. This may haveafter securing that additivity, linearity, variance homo-
genity and normality of residuals were reasonable limited the frequency of invalid data. Furthermore,
smoking data was obtained at the following annualfulfilled. Unfortunately, lp(a) even after transformation
failed to be reasonably normally distributed. The stat- control scans; only one of the ‘‘non-smokers’’ started
smoking. In spite of recommendations to stop smok-istical software package used was SPSS 10.0.
ing, unfortunately only one patient did so. This con-
sistency of data suggests reliable data concerning
smoking habits.
Beta-blockers were analysed because of earlierResults
reports of lower expansion among beta-blocker-
users.21,30,31 The possible effect of beta-blockage is hy-Table 1 shows the relationship between measured
pothesised to be caused by increased cross-linkage ofbiochemical and clinical variables and use of beta-
collagen- and elastin.32 Our observations confirm theseblockers, diet and smoking.
previous observations. However, adjustment for smok-The relationship between lipids, Lp(a), Ab-oxLDL,
ing removed the significant associations, indicatingAAA expansion, and ABI are tested upon beta-blocker
that the apparently benefits of beta-blockage could be,medication, dietary habits, supplements of vitamin
at least partly, due to limited smoking among betaand Q10 (antioxidant) tablets, and smoking habits.
blocker users. This seems logical because acute myo-Beta-blockers were associated with an adinose lipid
cardial infarction or other cardiac events are one ofprofile, lower expansion and better ABI. However,
the most common reasons for beta-blockage. Suchthese relationships disappeared after adjustment for
events could easily be more motivating to stop smok-smoking. Smoking was associated with aneurysmal
ing than general health campaigns or an accidentalexpansion but not with change in ABI.
finding of a asymptomatic small AAA. Furthermore,Besides the initial AAA size, S-triglycerides were
our earlier experience with a randomised interventioncorrelated to expansion, while only the initial ABI and
study with propranolol versus placebo could not showlipoprotein (A) were associated with the ABI-change-
any effect. However, this was mainly because of arate (Table 2). The initial AAA size remained sig-
high frequency of side effects and decreased qualitynificantly correlated to expansion after adjustment for
of life among those receiving propranolol, resulting insmoking, while the correlation between triglycerides
a low patient compliance in this study.33and expansion disappeared after adjustment for smok-
A significant correlation between s-triglycerides anding.
aneurysmal expansion was noticed. However, the cor-
relation disappeared after adjustment for any of the
other significant variables; beta-blockage, smoking, or
initial AAA size. In spite of many earlier prospective
Discussion studies of small AAA, only one study apart from
our own seems to have reported increased expansion
Only smoking and initial AAA size was correlated to associated to hyperlipidaemia.34 Furthermore, the as-
expansion, while only initial ABI and concentration of sociation seems controversial; some reports have ob-
lipoprotein (A) were correlated to ABI change rate. served increased levels of various lipids in AAA-
Most reports studying the relation between an- patients22,35,36 while others have failed to do so.23–25
eurysmal size and expansion have also found initial These different reports may be explained by different
AAA size of the AAA predictive for expansion15–19 but patient populations with different frequencies of co-
we were not able to confirm earlier reports of increased existing atherosclerotic diseases. Overall, the in-
expansion with increasing diastolic brachial blood consistency of association in the present and previous
pressure20,21 or systolic ankle blood pressure.16 studies suggests that lipids only seem to play a minor
Smoking has frequently been reported to be as- part in the progression of AAA, and thus indirectly
in the pathogenesis of AAA.sociated with AAA in case control studies,22–28 but
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The concentration of antibodies against malon- and can at this point not be recommended for moni-
toring or decision-making concerning antioxidant ther-dialdehyde-modified LDL has been shown to be
apy. However, the role of oxidised low densitysignificantly elevated in patients with AMI and ca-
lipoprotein remains unsolved.rotid-stenosis, but not in angina pectoris,37 and posi-
tively correlated to the progression of carotid stenosis.
This correlation was increased by presence of hy-
pertriglyceridaemia.5 However, the level of ab-oxLDL
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